Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More Details
Reasonable growth potential and slightly overvalued.
Share Price & News
How has Boston Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BSX's weekly volatility (3%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BSX underperformed the US Medical Equipment industry which returned 28.5% over the past year.
Return vs Market: BSX underperformed the US Market which returned 31.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Boston Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StShould You Investigate Boston Scientific Corporation (NYSE:BSX) At US$38.90?
2 weeks ago | Simply Wall StEstimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
1 month ago | Simply Wall StIs There More To The Story Than Boston Scientific's (NYSE:BSX) Earnings Growth?
Is Boston Scientific undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BSX ($37.93) is trading below our estimate of fair value ($37.93)
Significantly Below Fair Value: BSX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BSX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BSX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BSX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BSX is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (4.9x).
How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BSX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BSX's is expected to become profitable in the next 3 years.
Revenue vs Market: BSX's revenue (9.2% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: BSX's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BSX's Return on Equity is forecast to be high in 3 years time (20.6%)
How has Boston Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSX is currently unprofitable.
Growing Profit Margin: BSX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BSX is unprofitable, but has reduced losses over the past 5 years at a rate of 54.9% per year.
Accelerating Growth: Unable to compare BSX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BSX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.8%).
Return on Equity
High ROE: BSX has a negative Return on Equity (-0.54%), as it is currently unprofitable.
How is Boston Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($6.7B) exceed its short term liabilities ($3.7B).
Long Term Liabilities: BSX's short term assets ($6.7B) do not cover its long term liabilities ($11.8B).
Debt to Equity History and Analysis
Debt Level: BSX's debt to equity ratio (59.6%) is considered high.
Reducing Debt: BSX's debt to equity ratio has reduced from 89.8% to 59.6% over the past 5 years.
Debt Coverage: BSX's debt is not well covered by operating cash flow (16.5%).
Interest Coverage: BSX is unprofitable, therefore interest payments are not well covered by earnings.
What is Boston Scientific current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Mahoney (55 yo)
Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, its Chief Executive Officer since November 1, 2012 and has been its President since October...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD15.76M) is above average for companies of similar size in the US market ($USD10.58M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||7.17yrs||US$4.03m||0.020% |
|Executive VP of Global Operations||6.08yrs||US$3.20m||0.0065% |
|Executive VP & President of Interventional Cardiology||11.08yrs||US$4.03m||0.023% |
|VP, Global Controller & Chief Accounting Officer||1.67yrs||no data||0.0026% |
|Senior VP and Chief Information & Digital Officer||5.25yrs||no data||0.0015% |
|Vice President of Investor Relations||7.25yrs||no data||no data|
|Senior VP||3.33yrs||no data||0.0021% |
|Vice President of Global Marketing & New Business Development of Peripheral Interventions||no data||no data||no data|
|Senior VP of Human Resources||8.25yrs||no data||0.014% |
|Senior Vice President of Global Government Affairs||14.17yrs||no data||no data|
|Senior VP & President of Neuromodulation||9.5yrs||no data||0.017% |
Experienced Management: BSX's management team is seasoned and experienced (7.3 years average tenure).
|Lead Independent Director||4.83yrs||US$340.11k||0.0026% |
|Independent Director||5.67yrs||US$319.98k||0.0015% |
|Independent Director||5.92yrs||US$299.98k||0.00056% |
|Independent Director||7.17yrs||US$320.20k||0.0042% |
|Independent Director||4.92yrs||US$299.98k||0.0023% |
|Independent Director||4.67yrs||US$299.98k||no data|
|Independent Director||5.92yrs||US$324.98k||0.0052% |
|Independent Director||11.25yrs||US$302.47k||0.0039% |
|Independent Director||11.92yrs||US$319.98k||0.0026% |
Experienced Board: BSX's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BSX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boston Scientific Corporation's company bio, employee growth, exchange listings and data sources
- Name: Boston Scientific Corporation
- Ticker: BSX
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$53.753b
- Shares outstanding: 1.42b
- Website: https://www.bostonscientific.com
Number of Employees
- Boston Scientific Corporation
- 300 Boston Scientific Way
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BSX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 1992|
|BSX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1992|
|BSX||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||May 1992|
|BSX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 1992|
|0HOY||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1992|
|BSX||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||May 1992|
|BSXC||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||May 1992|
|BSX||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||May 1992|
|B1SX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1 COM||BR||BRL||Dec 2019|
|BSX.PRA||NYSE (New York Stock Exchange)||5.50% CNV PFD A||US||USD||May 2020|
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Ne...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/05 00:27|
|End of Day Share Price||2021/03/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.